by nms-sync | Jan 17, 2022 | News
Nerviano, 17 January 2022
The Shareholders’ Meeting of NMS Group S.p.A. (the “Company”) has appointed new Board of Directors for a three-year term. Tak-Wai (David) Wong has been named Chairman of the Board. Other newly appointed board members are...
by nms-sync | Nov 5, 2021 | News
Nerviano, 5 November 2021
Entrectinib, the kinase inhibitor drug that was invented and initially developed by Nerviano Medical Sciences (a member of NMS Group) and that is now marketed by Roche and partners, has won the Prix Galien Italia 2021 award as an...
by nms-sync | Oct 22, 2021 | News
Nerviano, 22 October 2021
Nerviano Medical Sciences (NMS Srl,) a member of NMS Group and a pharmaceutical company developing innovative new chemical entities (NCE) for the treatment of cancers, today announces that the U.S. Food and Drug Administration...
by nms-sync | Sep 29, 2021 | News
NMS Group is proud to be named by Pharma Tech Outlook as Top drug discovery and development solution providers in Europe for 2021 and featured in the cover of this special issue.
The annual list showcases companies that are providing cutting-edge drug...
by nms-sync | Sep 14, 2021 | News
Entrectinib, the kinase inhibitor drug that was initially discovered and developed by Nerviano Medical Sciences (a member of NMS Group) and that is now marketed by Roche and partners, has received approval for marketing and reimbursement from the Italian drug agency...
by nms-sync | Jun 30, 2021 | News
Nerviano, 30 June 2021
Accelera Srl and BiomimX® Srl have signed a non-exclusive commercial agreement following an intense scientific collaboration aimed at introducing and applying new technological solutions to the drug discovery process.
The...
Welcome and Check out our new motion picture!
Recent Comments